• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.

作者信息

Nabavi Seyed Fazel, Habtemariam Solomon, Clementi Emilio, Berindan-Neagoe Ioana, Cismaru Cosmin Andrei, Rasekhian Mahsa, Banach Maciej, Izadi Morteza, Bagheri Mahdi, Bagheri Mohammad Sadegh, Nabavi Seyed Mohammad

机构信息

Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Pharmacognosy Research Laboratories and Herbal Analysis Services, University of Greenwich, Central Avenue, Chatham-Maritime, Kent ME4 4TB, United Kingdom.

出版信息

Arch Med Sci. 2020 Apr 14;16(3):519-521. doi: 10.5114/aoms.2020.94504. eCollection 2020.

DOI:10.5114/aoms.2020.94504
PMID:32399097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7212214/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe3/7212214/9699ced2c21d/AMS-16-3-40393-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe3/7212214/9699ced2c21d/AMS-16-3-40393-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe3/7212214/9699ced2c21d/AMS-16-3-40393-g001.jpg

相似文献

1
Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.从严重急性呼吸综合征冠状病毒（SARS-CoV）和中东呼吸综合征冠状病毒（MERS-CoV）中吸取的教训：美国食品药品监督管理局（FDA）批准的阿贝尔森酪氨酸蛋白激酶2抑制剂可能有助于我们对抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。
Arch Med Sci. 2020 Apr 14;16(3):519-521. doi: 10.5114/aoms.2020.94504. eCollection 2020.
2
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.阿贝尔森激酶抑制剂是严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒融合的强效抑制剂。
J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1.
3
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL.药物信息学和分子动力学模拟研究揭示了 SARS-CoV-2 主蛋白酶 3CL 的潜在共价和 FDA 批准的抑制剂。
J Biomol Struct Dyn. 2021 Aug;39(13):4936-4948. doi: 10.1080/07391102.2020.1782768. Epub 2020 Jun 24.
4
Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV.对 2019 年新型冠状病毒的洞察——来自 SARS-CoV 和 MERS-CoV 的更新中期综述和经验教训。
Int J Infect Dis. 2020 May;94:119-124. doi: 10.1016/j.ijid.2020.03.071. Epub 2020 Apr 1.
5
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.Abl 激酶抑制剂在半融合前阻止冠状病毒 S 蛋白诱导的融合。
J Gen Virol. 2018 May;99(5):619-630. doi: 10.1099/jgv.0.001047. Epub 2018 Mar 20.
6
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
7
Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.2019冠状病毒病（COVID-19）的当前治疗选择——从严重急性呼吸综合征（SARS）和中东呼吸综合征（MERS）治疗中吸取的经验教训：一项系统评价方案
Ann Transl Med. 2020 Nov;8(22):1527. doi: 10.21037/atm-20-2340.
8
Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase.利用计算机建模和基于荧光共振能量转移的测定法，从新型已获 FDA 批准的药物中发现可抑制 MERS-CoV 解旋酶的化合物。
SAR QSAR Environ Res. 2021 Jan;32(1):51-70. doi: 10.1080/1062936X.2020.1857437. Epub 2021 Jan 6.
9
Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans.接种SARS-CoV-2、MERS-CoV或SARS-CoV疫苗后人体血清中中和抗体水平的比较与分析
Vaccines (Basel). 2021 Jun 2;9(6):588. doi: 10.3390/vaccines9060588.
10
Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).目前用于检测两种重要的贝塔冠状病毒的诊断方法：中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。
Pathol Res Pract. 2021 Sep;225:153565. doi: 10.1016/j.prp.2021.153565. Epub 2021 Jul 24.

引用本文的文献

1
A comparison of 7 commercial anti-SARS-CoV-2 antibody immunoassays.7种商用抗SARS-CoV-2抗体免疫测定法的比较。
Arch Med Sci. 2020 Aug 25;19(5):1281-1288. doi: 10.5114/aoms.2020.98361. eCollection 2023.
2
Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study.早期淋巴细胞计数降低会增加新冠病毒肺炎患者的病情严重程度和死亡风险：一项基于医院的病例队列研究
Arch Med Sci. 2020 Sep 15;19(5):1303-1313. doi: 10.5114/aoms.2020.99006. eCollection 2023.
3
Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases.

本文引用的文献

1
Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.2019冠状病毒病大流行时代的降脂治疗与肾素-血管紧张素-醛固酮系统抑制剂
Arch Med Sci. 2020 Apr 14;16(3):485-489. doi: 10.5114/aoms.2020.94503. eCollection 2020.
2
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence.基于现有证据对 2019 年新型冠状病毒（SARS-CoV-2）的回顾。
Int J Antimicrob Agents. 2020 Jun;55(6):105948. doi: 10.1016/j.ijantimicag.2020.105948. Epub 2020 Mar 19.
3
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
靶向人类蛋白的抗病毒药物发现和再利用研究：以蛋白激酶为重点。
Viruses. 2023 Feb 19;15(2):568. doi: 10.3390/v15020568.
4
Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review.2019年冠状病毒病大流行对癌症患者及其治疗的全球影响：一项系统综述
Clin Complement Med Pharmacol. 2022 Dec;2(4):100041. doi: 10.1016/j.ccmp.2022.100041. Epub 2022 Apr 25.
5
Perspectives on the Use of Small Noncoding RNAs as a Therapy for Severe Virus-Induced Disease Manifestations and Late Complications.关于使用小非编码RNA治疗严重病毒诱导疾病表现和晚期并发症的观点。
Bionanoscience. 2022;12(3):994-1001. doi: 10.1007/s12668-022-00977-z. Epub 2022 May 4.
6
Exploring the interaction of quercetin-3-O-sophoroside with SARS-CoV-2 main proteins by theoretical studies: A probable prelude to control some variants of coronavirus including Delta.通过理论研究探索槲皮素-3-O-槐糖苷与SARS-CoV-2主要蛋白的相互作用：控制包括德尔塔在内的一些冠状病毒变体的可能前奏。
Arab J Chem. 2021 Oct;14(10):103353. doi: 10.1016/j.arabjc.2021.103353. Epub 2021 Jul 28.
7
Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.一些从实验室到临床的β冠状病毒的发病机制、治疗靶点和有效抑制剂。
Infect Genet Evol. 2021 Sep;93:104944. doi: 10.1016/j.meegid.2021.104944. Epub 2021 May 28.
8
Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.自噬的药理学调节剂作为 COVID-19 治疗的一种潜在策略。
Int J Mol Sci. 2021 Apr 15;22(8):4067. doi: 10.3390/ijms22084067.
9
Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?《权力的游戏》第八季之“巅峰对决”：新冠病毒中的RAS与生殖激素——我们能否终结这一病毒系列？
Arch Med Sci. 2020 Jun 27;17(2):275-284. doi: 10.5114/aoms.2020.96604. eCollection 2021.
10
Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments.2019年冠状病毒病：从临床表现、发病机制到新型管理方法与治疗的简要综述
Front Oncol. 2020 Oct 29;10:572329. doi: 10.3389/fonc.2020.572329. eCollection 2020.
洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
4
Convalescent plasma as a potential therapy for COVID-19.康复期血浆作为治疗新冠肺炎的一种潜在疗法。
Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.
5
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
6
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.沙卡替尼抑制体外中东呼吸综合征冠状病毒复制。
Viruses. 2018 May 24;10(6):283. doi: 10.3390/v10060283.
7
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.Abl 激酶抑制剂在半融合前阻止冠状病毒 S 蛋白诱导的融合。
J Gen Virol. 2018 May;99(5):619-630. doi: 10.1099/jgv.0.001047. Epub 2018 Mar 20.
8
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.阿贝尔森激酶抑制剂是严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒融合的强效抑制剂。
J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1.